QCIL Stock Overview
A pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Quality Chemical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | USh56.00 |
| 52 Week High | USh70.00 |
| 52 Week Low | USh52.00 |
| Beta | -0.22 |
| 11 Month Change | 1.82% |
| 3 Month Change | 5.66% |
| 1 Year Change | -20.00% |
| 33 Year Change | -44.00% |
| 5 Year Change | -61.48% |
| Change since IPO | -78.63% |
Recent News & Updates
Recent updates
Shareholder Returns
| QCIL | UG Pharmaceuticals | UG Market | |
|---|---|---|---|
| 7D | 1.8% | 3.5% | 0.3% |
| 1Y | -20.0% | 17.0% | 9.0% |
Return vs Industry: QCIL underperformed the UG Pharmaceuticals industry which returned 17% over the past year.
Return vs Market: QCIL underperformed the UG Market which returned 9% over the past year.
Price Volatility
| QCIL volatility | |
|---|---|
| QCIL Average Weekly Movement | 1.3% |
| Pharmaceuticals Industry Average Movement | 4.0% |
| Market Average Movement | 1.7% |
| 10% most volatile stocks in UG Market | 3.3% |
| 10% least volatile stocks in UG Market | 0.6% |
Stable Share Price: QCIL has not had significant price volatility in the past 3 months.
Volatility Over Time: QCIL's weekly volatility (1%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | n/a | Ajay Pal | www.ciplaqcil.co.ug |
Quality Chemical Industries Limited, a pharmaceutical manufacturing company, manufactures and delivers anti-retroviral, anti-malarial, and hepatitis B medicines. The company offers Duovir-N; Lamivudine and Zidovudine; Efavir 60; Duomune; Nevirapine; Efavirenz, Lamivudine, and Tenofovir; and Dolutegravir, Lamivudine, and Tenofovir tablets for the treatment of HIV infection. It also offers Lumartem/Lumet tablets for the treatment of malaria; and Texavir and Zentair for the treatment of Hepatitis B. The company was formerly known as Cipla Quality Chemical Industries Limited and changed its name to Quality Chemical Industries Limited in February 2024.
Quality Chemical Industries Limited Fundamentals Summary
| QCIL fundamental statistics | |
|---|---|
| Market cap | USh204.51b |
| Earnings (TTM) | USh31.76b |
| Revenue (TTM) | USh265.34b |
6.4x
P/E Ratio0.8x
P/S RatioIs QCIL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QCIL income statement (TTM) | |
|---|---|
| Revenue | USh265.34b |
| Cost of Revenue | USh162.42b |
| Gross Profit | USh102.92b |
| Other Expenses | USh71.16b |
| Earnings | USh31.76b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 8.70 |
| Gross Margin | 38.79% |
| Net Profit Margin | 11.97% |
| Debt/Equity Ratio | 0% |
How did QCIL perform over the long term?
See historical performance and comparison